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Background: Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) has gained
acceptance in the treatment of peritoneal carcinomatosis (PC) with reported morbidity and mortality
rates of 27e56% and 0e11% respectively. The safety and outcome of such major operation in the elderly
remains unclear. We report our experience at a high volume tertiary center.
Method: A total of 170 consecutive patients underwent CRS-HIPEC for peritoneal carcinomatosis between
March 2007 and July 2012. Mitomycin C (88.8%) was administered intraperitoneally at 42 C for 90 min.
Patients were categorized into two groups according to the age at the time of surgery: Group 1 (65
years-old) and Group 2 (>65 years-old). Differences between the groups were analyzed. Univariate and
multivariate analyses were performed to identify variables associated with major morbidity.
Results: Of the 170patients, 35were older than 65 years. The twomost common tumor siteswere colorectal
and appendiceal cancer. The perioperativemorbidity andmortality rates in the elderlywere 18.8% and 8.6%
respectively. Gender, tumor type, estimated blood loss >400 mL, intraoperative blood transfusion, oper-
ative time >6 h, bowel anastomosis, intraoperative PCI >16, and extent of cytoreduction (D PCI) were not
associated with major morbidity in the older group (p > 0.05). At a median follow-up of 15.7 months (0.2
e53.5 months), recurrence rate for colorectal/appendiceal PC at 1 year was 48.0% in Group 1 and 44.3% in
Group 2 (p ¼ NS). Median survival for the colorectal/appendiceal carcinomatosis patients in Group 1
(n ¼ 81) was 29.79 (SE 4.7) months and in Group 2 (n ¼ 20) was 21.2 (SE 3.0) months, (p ¼ 0.06, NS).
Conclusion: CRS-HIPEC procedures for peritoneal carcinomatosis in the elderly demonstrate comparable
perioperative outcome in well-selected patients. Optimal cytoreduction was achieved in the majority of
cases and survival was not signiﬁcantly different from that of the younger group.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
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Cytoreductive surgery (CRS) with heated intraperitoneal chemo-
therapy (HIPEC) has gained acceptance in the treatment of select
cases of peritoneal carcinomatosis (PC) [1e3]. For PC of colorectal
cancer origin speciﬁcally, this treatment has been shown to be efﬁ-
cacious in multiple Phase II studies [4,5]. Further, it has been proven
superior to systemic chemotherapy alone with regards to overall
survival in one randomized controlled trial [3]. The procedure,
however, is labor intensive, technically demanding, and rife with
potential complications. Themajority of authors reportmorbidity and
mortality rates of 27e56% and 0e11% respectively [6e12] (Table 1).
As the median age of patients increases, the beneﬁt of such an
aggressive approach in the elderly remains unclear. There is a
paucity of literature on the effect of age on the outcome of CRS and
HIPEC in the treatment of PC.
Presented in this study are results from a tertiary medical center
in the United States performing a high volume of CRS and HIPEC for
PC. The speciﬁc aim of this analysis was to investigate the outcomes
of this approach in patients>65 years of age. These results will help
better understand the safety and feasibility of this treatment mo-
dality in the elderly population.
Methods
Study design
The records of all patients receiving CRS and HIPEC for PC from a
multitude of primary tumor sites between March 2007 and July
2012 were reviewed. The procedures were performed at a single
tertiary center by two different surgical oncologists. Data for this
analysis were retrieved from a prospectively maintained database.
The analysis focused on the subgroup of patients >65 years of age,
and had as its endpoints length of stay, perioperative major
morbidity and 90-day mortality. Institutional review board (IRB)
approval was obtained for this study.
Co-morbidities
Diabetes mellitus was deﬁned as a fasting blood glucose
120 mg/dl on two occasions or current treatment with insulin or
oral hypoglycemic agent(s). Hypertension (HTN) was deﬁned as a
resting blood pressure of 140/90 mmHg on two separate occasions
or current treatment with anti-hypertensive medication(s). Cardio-
vascular disease comprised any previous coronary artery stenosis/
occlusion treated with angiographic or surgical revascularization,Table 1
Existing series on CRS/HIPEC for peritoneal carcinomatosis.
Author Year Number
(n)
Age (mean) Morbidity
%
Mortality
%
Sugarbaker [6] 1999 155 e 27 2
Sugarbaker [7] 2006 356 Median 58 19 2
Smeenk [8] 2007 323 Median 57 49.5 5.8
Levine [9] 2007 460 53  12 43 4.8
Gusani [10] 2008 122 Median 53 29.8 1.6
Saxena [11] 2009 145 53  11 38 5
Elias [12] 2010 523 53  12 31 3.3current treatment with one or more antiarrhythmic agent(s), and/or
a diagnosis of atrial ﬁbrillation. Chronic renal insufﬁciency was
deﬁned by a serum creatinine 1.5 times the upper limit of normal,
or a calculated creatinine clearance <30 mL/min.Diagnosis and treatment
Patients were most often referred to our institution after a
diagnosis of PC had been established at an outside hospital. After
initial evaluation at our institution, a contrast-enhanced cross-
sectional imaging study (CT scan or MRI) of the chest, abdomen,
and pelvis was obtained as a means of quantifying peritoneal dis-
ease burden and ruling out extra-abdominal spread. Unresectable
visceral hepatic metastases or thoracic metastases were contrain-
dications to CRS and HIPEC. If tissue had been obtained for diag-
nosis at the outside hospital, repeat pathological analysis was
performed. All patients were evaluated by amultidisciplinary team.
Treatment was then customized according to pathologic features,
response to chemotherapy, tumor burden on imaging study and
intraoperatively by laparoscopy, disease amenable to potential
complete cytoreduction and patient’s condition.
Although advanced chronological age did not preclude surgical
consideration, an ECOG performance status of 0e2 was required.
All patients 50 years of age, and select patients <50, received a
pre-operative cardiology evaluation. A signiﬁcant impairment in
cardiac, pulmonary, hepatic, or renal function was a contraindica-
tion to surgery.
Patients with PC from colorectal cancer were initially treated
with oxaliplatin- or irinotecan-based systemic chemotherapy, and a
progression-free interval of at least 3 months was preferred before
a recommendation of CRS and HIPEC was made. A more selective
approach was applied to gastric origin PC, for which a sustained
radiologic response (6 months or more) on systemic chemotherapy
was generally required.
Surgery commenced with a diagnostic laparoscopy to assess the
feasibility of thorough cytoreduction. If the disease burden was
limited, a midline laparotomy was made and the patient was
explored. The peritoneal cancer index was recorded (Fig. 1) [13]. If
not previously performed, the primary tumor was resected. A
greater omentectomy was usually performed, followed by tumor
debulking as dictated by the distribution of disease. This included
resection of all intra-abdominal organ(s) grossly involved by
visceral peritoneal spread, and stripping of all parietal peritoneal
surfaces affected, including those of the subdiapragmatic spaces,
the paracolic recesses, and the anterior abdominal wall. The
completeness of cytoreduction was then recorded using the Jac-
quet/Sugarbaker Classiﬁcation System: CCR-0, no residual macro-
scopic disease; CCR-1, residual peritoneal deposits <2.5 mm; CCR-
2, residual deposits between 2.5 mm and 2.5 cm; CCR-3, residual
deposits >2.5 cm or conﬂuent tumors. The aim was a complete
cytoreduction, deﬁned as eradication of all peritoneal nodules
2.5 mm in diameter (CCR 0e1) [13,14].
Following cytoreduction, HIPEC was performed as previously
described. The closed abdomen technique was used in all cases.
Mitomycin C was the most common agent used in our series and
was administered over two doses for a 90-min perfusion period
with a target intraperitoneal temperature of 41e43 C. A 40 mg
dose was used and split between 30 mg for the ﬁrst 60 min and
Figure 1. Peritoneal cancer index (PCI) [13].
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ﬂow was 700 mL/min. A 30% dose reduction was applied to elderly
patients, with previous chemotherapy or extensive surgical cy-
toreduction. In 13.5% of cases based on the assessment of the
operating surgeon and tumor origin (Gyn malignancy and meso-
thelioma) cisplatin/other agents were used instead. Gastrointes-
tinal anastomoses were performed after the conclusion of the
perfusion. Following surgery, patients were typically extubated and
transferred to a telemetry unit for 24e48 h of initial monitoring.
Major postoperative morbidity was deﬁned according to the
Clavien-Dindo Classiﬁcation System (IIIeIV) and included any
complication requiring endoscopic, radiologic or surgical inter-
vention, or any life-threatening postoperative condition requiring
intensive care unit management [15]. Perioperative mortality was
deﬁned as any death within 30 days of surgery or during the same
hospitalization.Surveillance
Surveillance consisted of a physical examination, complete
blood count, serum chemistry, CEA level if appropriate, and
contrast-enhanced CT scan (or MRI) of the chest, abdomen and
pelvis every 3 months for the ﬁrst two years, and then every 6
months thereafter. Diagnosis of recurrence was generally estab-
lished by radiographic means, with tissue biopsy in select circum-
stances. All of our patients were followed postoperatively by an
oncology group. Patients with colorectal and appendiceal cancer
origin were all treated with adjuvant systemic therapy. Recurrence
and survival data were limited to a subset of patients with colo-
rectal/appendiceal cancer, to allow a meaningful comparison be-
tween the same tumor type.Statistical analysis
Continuous variables were presented as mean  standard de-
viation and compared using Student’s t-test for data with a normal
distribution. Categorical variables were expressed as valid per-
centages and compared using the chi-squared test or Fisher’s exact
test as appropriate. A multivariate analysis for independent pre-
dictors associated with morbidity was conducted for the overallcohort, and the following variables were analyzed: age>65 years of
age, gender, tumor type, estimated blood loss (>400 mL), intra-
operative blood transfusion, operative time (>6 h), bowel anasto-
mosis, intraoperative PCI > 16, and extent of cytoreduction (D PCI).
A p-value of <0.05 was considered signiﬁcant. Statistical analysis
was carried out using SPSS 19.0 (Chicago, IL).Results
During the study period, 170 patients underwent CRS and HIPEC
for PC with curative intent. Of these patients, 135 (79.4%) were 65
years of age or younger (Group 1), and 35 (20.6) were older than 65
(Group 2). The clinical data of the two groups are summarized in
Table 2. There were no statistical differences in gender or in the
prevalence of co-morbidities. The two most common tumor sites
were colorectal and appendiceal cancer.
The intraoperative outcomes are outlined in Table 3. The extent
of peritoneal involvement as deﬁned by the pre-operative PCI was
not signiﬁcantly different between groups. Complete cytoreduction
(CCR 0e1) was achieved in 78.6% and 82.4% in Groups 1 and 2
respectively (p ¼ NS). No differences were noted in length of sur-
gery, intra-operative complications, blood loss, or transfusion rates.
Review of all postoperative outcomes is shown in Table 4. The
postoperative major morbidity rate at 30 days in younger patients
was lower than that of the older group (21.6% Group 1 vs. 18.8%
Group 2), however this difference was not statistically signiﬁcant,
(p ¼ 0.056). No statistically difference in major morbidity (IIIeIV)
was noted based on chemotherapy agents used intraoperatively
(p ¼ NS). None of the patients in the cisplatin group experienced
side effects such as renal dysfunction or neuropathy. Although not
statistically signiﬁcant (p ¼ NS), the hematologic toxicity (transient
neutropenia) was noted to be higher in the Mitomycin group (11.8%
vs. 0%). However, the toxicity rate was equally distributed among
both groups: Group 1 (10.4%) vs. Group 2 (11.4%) (p ¼ 0.767). None
of the following variables independently predictedmorbidity in the
overall cohort: age >65 years of age, gender, tumor type, estimated
blood loss (>400 mL), intraoperative blood transfusion, operative
time (>6 h), bowel anastomosis, intraoperative PCI> 16, and extent
of cytoreduction (D PCI). There were no intraoperative deaths seen
in either group. The perioperative (30 day) mortality rate in elderly
Table 2
Clinical data of 170 patients undergoing CRS/HIPEC for peritoneal carcinomatosis:
Group 1 (65 years) vs. Group 2 (>65 years).
Variables Group 1
(65 years)
n ¼ 135
Group 2
(>65 years)
n ¼ 35
P-value
Male gender (%) 58 (43.0) 18 (51.4) 0.369
Age (mean  SD) 51.2 (8.9) 70.2 (4.8) <0.001
Co-morbidities
Hypertension 21(15.6) 19(57.6) <0.001
COPD/sever lung disease 3(2.3) 4(12.1) 0.014
Cardiovascular disease 5(3.9) 9(27.3) <0.001
Diabetes mellitus 10(7.8) 6(18.2) 0.073
Chronic renal insufﬁciency 1(0.7) 0(0.0) 0.796
Severe liver disease 5(3.9) 0(0.0) 0.584
Pre-operative lab
Albumin (gm/L) 4.1 (0.5) 3.9 (0.4) 0.101
Creatinine (mg/dL) 0.93 (0.7) 0.99 (0.3) 0.646
Hemoglobin (g/dL) 12.4 (1.6) 12.3 (1.8) 0.841
Primary tumor site (n,%)
Colorectal 39 (28.9) 11 (31.4) 0.739
Appendiceal 42 (31.3) 9 (25.7)
Pseudomyxoma peritonei 14 (10.4) 2 (5.7)
Gastric 10 (7.4) 2 (5.7)
Ovarian 9 (6.7) 2 (5.7)
Others 21 (15.6) 9 (25.7)
ASA score (n,%) 0.066
1 0 0
2 25 (18.5) 2(5.7)
3 97 (71.9) 26 (74.3)
4 13 (9.6) 7 (20.0)
ECOG performance status (n,%) 0.108
0 14(18.9) 0(0.0)
1 56(75.7) 16(88.9)
2 4(4.5) 2(11.1)
Table 3
Operative data of 170 patients undergoing CRS/HIPEC for peritoneal carcinomatosis:
Group 1 (65 years) vs. Group 2 (>65 years).
Variables Group 1
(65 years)
n ¼ 135
Group 2
(>65 years)
n ¼ 35
P-value
Operative time (minutes,
mean)a (SD)
372 (132.3) 344 (130) 0.271
Estimated blood loss (ml,
mean) (SD)
706.6 (820.1) 928.4 (1575.4) 0.262
Blood transfusion, n (%) 52 (38.5) 16 (45.7) 0.439
Intra-operative PCI score n (%)
<16 69 (51.5) 21 (61.8) 0.283
16 65 (48.5) 13 (38.2)
Mean (SD) 16.2 (9.2) 15.3 (8.4) 0.616
Post-CRS PCI, mean (SD) 3.5 (3.8) 3.2 (4.8) 0.295
D PCI, mean (SD) 12.5 (7.0) 11.7 (6.3) 0.834
CC score (Jacquet) n (%)
CCR 0e1 103 (78.6) 28 (82.4) 0.632
CCR 2e3 28 (21.4) 6 (17.6)
CC score (Lyon) n (%)
R0 48 (42.5) 14 (51.5) 0.501
R1 37 (32.7) 9 (33.3)
R2 28 (24.8) 4 (14.8)
Chemotherapeutic agent
Mitomycin C, n (%) 120(88.9) 31(88.6) 0.684
Cisplatin/others 19(14.0) 4(11.4)
Number of organs
resected, mean
4.1 (2.6) 3.5 (1.8) 0.214
Number of bowel anastomoses n (%)
0 50 (37.0) 19 (54.3) 0.172
1 62 (45.9) 11 (31.4)
2 or more 23 (17.0) 5 (14.3)
Intra-operative
complications
0 0 1.0
a Including HIPEC (90 min).
Table 4
Post-operative outcomes of 170 patients undergoing CRS/HIPEC for peritoneal
carcinomatosis: Group 1 (65 years) vs. Group 2 (>65 years).
Variable Group 1
(65 years)
n ¼ 135
Group 2
(>65 years)
n ¼ 35
P-value
Hospital stay [days],
mean (SD)
11.7 (15.5) 12.6 (15.8) 0.784
ICU admission, n (%) 26 (19.7) 10 (30.3) 0.187
Reoperation (90 days) 28(21.2) 5(14.3) 0.360
90-day Outcome:
Morbidity, n (%)
None 61(48.0) 10(32.2) 0.115
Clavian IeII 37(29.1) 15(48.4)
Clavian IIIeIV 29(22.8) 6(19.4)
-Intraabdominal abscess 15(11.4) 2(5.9) 0.529
-Wound infection 6(4.6) 2(5.9) 0.669
-Leak/ﬁstula 14(10.7) 2(5.9) 0.528
-Pulmonary embolism 3(2.3) 2(5.9) 0.274
-DVT 3(2.3) 3(8.8) 0.104
-Respiratory failure 8(6.2) 2(5.9) 0.953
-Bleeding 1(0.74) 1(2.8) 0.847
Mortality (Clavian V), n (%) 8(5.9) 4(11.4) 0.272
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11.4% (n ¼ 4) in Groups 1 and 2 respectively (p ¼ NS). When
comparing results of our colorectal and appendiceal PC group we
report a 30 day mortality rate of 0% (Group 1) vs. 5% (Group 2)
(p ¼ 0.198) and 90 day mortality rate of 2.5% (Group 1) vs. 5%
(Group 2) (p ¼ 0.488).
The median follow up for all patients diagnosed with PC of
colorectal or appendiceal origin was 15.7 months (1.2). Recur-
rence rate for colorectal/appendiceal PC at 1 year was 48.0% in
Group 1 and 44.3% in Group 2 (p ¼ NS) Fig. 2. The median survival
for colorectal/appendiceal PC patients was 29.8 (SE 4.7) months in
Group 1 (n ¼ 81) and 21.2 (SE 3.0) months in Group 2 (n ¼ 20). The
difference was not statistically signiﬁcant (p ¼ 0.06) (Fig. 3).
Discussion
Modern systemic therapy regimens demonstrated improved tu-
mor response rates over older regimens, translating into gains inFigure 2. Overall recurrence of 101 patients undergoing CRS/HIPEC for peritoneal
carcinomatosis of appendiceal/colorectal origin (Group 1/Group 2) p ¼ 0.708.
Figure 3. Overall survival of 101 patients undergoing CRS/HIPEC for peritoneal carci-
nomatosis of appendiceal/colorectal origin (Group 1/Group 2) p ¼ 0.06, NS.
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vival in patients with metastatic colorectal cancer increased from 5.2
to 12.6 months [16,17]. The survival beneﬁt of CRS-HIPEC in selected
patients has been established by large non-randomized single/
multicenter studies and one prospective randomized trial [1e5].
Verwaal et al. demonstrated a survival beneﬁt in patients
receiving CRS-HIPEC plus adjuvant chemotherapy, vs. chemo-
therapy alone (median survival 22.3 vs. 12.6 months, respectively)
[3]. In addition, the safety of CRS-HIPEC in patients with various
malignancies has been well established with an acceptable
morbidity rate of 12e66% and mortality rate of 0e12% [6e12].
In thepastdecade, advancedsurgical techniquesandperioperative
management have reduced age-related contraindications to major
surgeries. Published series have conﬁrmed that age alone is not a
contraindication to high-morbidity operations [18,19]. With a pro-
gressively aging population, there has been some controversy sur-
rounding thequestionofwhether cytoreductive surgerywithHIPEC is
advisable and feasible in the elderly. It is unclear if advanced age is a
contraindication for such an aggressive procedure and whether out-
comes comparable to the younger population can be achieved.
We report our series of 35 patients 65 years or older with PC
treated with CRS-HIPEC in a single center and ﬁnd it a safe and
efﬁcacious procedure. To our knowledge, this is the largest study
analyzing the outcome of CRS-HIPEC in the elderly. Only one series
[20] reported their experience of CRS in the elderly, but did not
evaluate the role of HIPEC.
Baratti et al. and other large studies summarized in Table 1
identiﬁed patients at highest risk for complications of CRS-HIPEC
and demonstrated that age was not an independent risk factor
[6e12,21]. Factors persistently signiﬁcant for poor outcome were
high PCI scores, number of visceral resections, extent of cytor-
eduction, type of chemotherapy agent, and poor performance sta-
tus [3,21]. Our series demonstrates that CRS-HIPEC is an acceptable
method in the elderly with comparable morbidity/mortality rates
in the treatment of PC. Our perioperative (30 day) mortality (8.6%)
and 90 day morbidity (19.4%) rates were comparable to that of
other published series. Despite the higher rate of cardiovascular co-
morbidity in our series in the elderly group, the performance status
was similar in both groups. Additionally, the study demonstratesmeaningful long term survival in the treatment of colorectal and
appendiceal carcinomatosis among both groups.
Similar to other published series on this topic, the main limi-
tation of our study is its retrospective nature and relatively small
sample size. Despite this being the largest series of older patients
undergoing HIPEC, the low power of the study may have led to the
lack of statistical signiﬁcance seen for the differences in the
morbidity rates between the groups. In addition, our ﬁndings are
subject to selection bias, since we only included older patients who
had an adequate performance status. As a result, our ﬁndings are
not generalizable to all patients over 65 years of age. Indeed, we
believe that rigorous patient selection is the key tomaintaining low
complications rates for older patients.
Conclusion
In conclusion, CRS with HIPEC can achieve comparable periop-
erative and survival outcomes in well-selected patients older than
65 years. Age itself should not be a contraindication to aggressive
surgical treatment of PC.When considering an older patient for CRS-
HIPEC, assessment of the patient’s performance status is critical.
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